<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METRONIDAZOLE- metronidazoleÂ tabletÂ </strong><br>Liberty Pharmaceuticals, Inc.<br></p></div>
<h1>METRONIDAZOLE TABLETS USP<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_829604c7-b2fd-4972-9244-9ff50d61f863"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">333</p>
<p>334</p>
<p>Rev. A 6/2011</p>
<p><span class="Bold">Rx only</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. </p>
<div class="Warning">
<a name="LINK_c5417a9f-ffa6-4c59-a138-aec370f0df1a"></a><a name="section-1.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">WARNING</span></p>
<p>Metronidazole has been shown to be carcinogenic in mice and rats (see <span class="Bold"><a href="#LINK_197af00a-6e39-4443-aa3b-5b836d585c7f">PRECAUTIONS</a></span>). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the <span class="Bold"><a href="#LINK_ac51fa9e-78d7-46f5-86d6-73444ebb496d">INDICATIONS AND USAGE</a></span> section below.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_3fe5b803-5b3a-4f36-aa9a-f0f03c25069c"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Metronidazole, USP is an oral synthetic antiprotozoal and antibacterial agent, 1-(Î²-hydroxyethyl)-2-methyl-5-nitroimidazole, which has the following structural formula:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5911e8f2-1b3a-4222-b997-d2a1c9a9f535&amp;name=metronidazole-for-pliva-1.jpg"></div>
<p>C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">3 </span>           M.W. 171.15</p>
<p>Each tablet for oral administration contains 250 mg or 500 mg of metronidazole, USP. Inactive ingredients include microcrystalline cellulose, crospovidone, colloidal silicon dioxide and hydrogenated vegetable oil.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_ddbb9dc7-2786-4e42-96b2-66e1e784fdf6"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Disposition of metronidazole in the body is similar for both oral and intravenous dosage forms, with an average elimination half-life in healthy humans of eight hours.</p>
<p>The major route of elimination of metronidazole and its metabolites is via the urine (60 to 80% of the dose), with fecal excretion accounting for 6 to 15% of the dose. The metabolites that appear in the urine result primarily from side-chain oxidation [1-(Î²-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation, with unchanged metronidazole accounting for approximately 20% of the total. Renal clearance of metronidazole is approximately 10 mL/min/1.73 m<span class="Sup">2</span>.</p>
<p>Metronidazole is the major component appearing in the plasma, with lesser quantities of the 2-hydroxymethyl metabolite also being present. Less than 20% of the circulating metronidazole is bound to plasma proteins. Both the parent compound and the metabolite possess <span class="Italics">in vitro</span> bactericidal activity against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of anaerobic bacteria and <span class="Italics">in vitro </span>trichomonacidal activity.</p>
<p>Metronidazole appears in cerebrospinal fluid, saliva, and human milk in concentrations similar to those found in plasma. Bactericidal concentrations of metronidazole have also been detected in pus from hepatic <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>.</p>
<p>Following oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. </p>
<p>Plasma concentrations of metronidazole are proportional to the administered dose. Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma levels in males are generally lower.</p>
<p>Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole. However, plasma clearance of metronidazole is decreased in patients with decreased liver function.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_238424af-29ca-4f6f-9032-dd5f423e4664"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5fead216-ef1a-43cb-a05d-8fca47d4ec5a"></a><a name="section-3.1.1"></a><p></p>
<h3>Trichomonas vaginalis, Entamoeba histolytica</h3>
<p class="First">Metronidazole possesses direct trichomonacidal and amebacidal activity against <span class="Italics">T. vaginalis </span>and <span class="Italics">E. histolytica</span>. The <span class="Italics">in vitro</span> minimal inhibitory concentration (MIC) for most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of these organisms is 1 mcg/mL or less.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_81e5f8df-03dd-4422-bcb7-a6abd53695e4"></a><a name="section-3.1.2"></a><p></p>
<h3>Anaerobic Bacteria</h3>
<p class="First">Metronidazole is active <span class="Italics">in vitro </span>against most obligate anaerobes but does not appear to possess any clinically relevant activity against facultative anaerobes or obligate aerobes. Against susceptible organisms, metronidazole is generally bactericidal at concentrations equal to or slightly higher than the minimal inhibitory concentrations. Metronidazole has been shown to have <span class="Italics">in vitro </span>and clinical activity against the following organisms:</p>
<p>Anaerobic gram-negative bacilli, including:</p>
<p><span class="Italics">Bacteroides </span>species including the <span class="Italics">Bacteroides fragilis </span>group (<span class="Italics">B. fragilis, B. distasonis, B.</span><span class="Italics">ovatus, B. thetaiotaomicron, B. vulgatus</span>)</p>
<p><span class="Italics">Fusobacterium </span>species</p>
<p>Anaerobic gram-positive bacilli, including:</p>
<p><span class="Italics">Clostridium </span>species and susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Eubacterium</span></p>
<p>Anaerobic gram-positive cocci, including:</p>
<p><span class="Italics">Peptococcus niger</span></p>
<p><span class="Italics">Peptostreptococcus </span>species</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8fbc9f4e-f84c-4220-9801-1f69ba776650"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Tests</h2>
<p class="First">Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to metronidazole; however, the rapid, routine susceptibility testing of individual isolates of anaerobic bacteria is not always practical, and therapy may be started while awaiting these results.</p>
<p>Quantitative methods give the most precise estimates of susceptibility to antibacterial drugs. A standardized agar dilution method and a broth microdilution method are recommended.<span class="Sup">1</span></p>
<p>Control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are recommended for standardized susceptibility testing. Each time the test is performed, one or more of the following <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> should be included: <span class="Italics">Clostridium perfringens </span>ATCC 13124, <span class="Italics">Bacteroides fragilis </span>ATCC 25285, and <span class="Italics">Bacteroides thetaiotaomicron </span>ATCC 29741. The mode metronidazole MICs for those three <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are reported to be 0.25, 0.25, and 0.5 mcg/mL, respectively.</p>
<p>A clinical laboratory is considered under acceptable control if the results of the control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are within one doubling dilution of the mode MICs reported for metronidazole. </p>
<p>A bacterial isolate may be considered susceptible if the MIC value for metronidazole is not more than 16 mcg/mL. An organism is considered resistant if the MIC is greater than 16 mcg/mL. A report of â€œresistantâ€? from the laboratory indicates that the infecting organism is not likely to respond to therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_ac51fa9e-78d7-46f5-86d6-73444ebb496d"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_11824474-8d4c-489c-9318-077db5b4938c"></a><a name="section-4.1"></a><p></p>
<h2>Symptomatic <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></h2>
<p class="First">Metronidazole, USP is indicated for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_53b9a260-4515-4af5-8f73-aec26319a3cf"></a><a name="section-4.2"></a><p></p>
<h2>Asymptomatic <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></h2>
<p class="First">Metronidazole, USP is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span>, or cervical erosion.Â  Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c6d2104c-0b90-4350-993a-f659a65324c4"></a><a name="section-4.3"></a><p></p>
<h2>Treatment of Asymptomatic Consorts</h2>
<p class="First"><span class="Italics">T. vaginalis </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole, USP in cases of reinfection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_21e5c408-88d8-44bf-89bf-25d02e8a6f59"></a><a name="section-4.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></h2>
<p class="First">Metronidazole, USP is indicated in the treatment of acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> (amebic <span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">dysentery</span>) and amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span>. In amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span>, metronidazole, USP therapy does not obviate the need for <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> or drainage of pus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f6333348-154b-4e71-b72e-b67668d98a58"></a><a name="section-4.5"></a><p></p>
<h2>Anaerobic <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span></h2>
<p class="First">Metronidazole, USP is indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole, USP therapy. In a mixed aerobic and anaerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, antimicrobials appropriate for the treatment of the aerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be used in addition to metronidazole, USP.</p>
<p>In the treatment of most serious anaerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the intravenous form of metronidazole, USP is usually administered initially. This may be followed by oral therapy with metronidazole, USP at the discretion of the physician.</p>
<p>INTRA-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">ABDOMINAL INFECTIONS</span>,<span class="Bold">Â  </span>including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, intra-<span class="product-label-link" type="condition" conceptid="4326255" conceptname="Abdominal abscess">abdominal abscess</span>, and <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span>, caused by <span class="Italics">Bacteroides </span>species including the <span class="Italics">B. fragilis </span>group (<span class="Italics">B. fragilis,</span><span class="Italics">B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus</span>), <span class="Italics">Clostridium </span>species, <span class="Italics">Eubacterium </span>species, <span class="Italics">Peptococcus niger, </span>and <span class="Italics">Peptostreptococcus </span>species.</p>
<p>SKIN AND SKIN STRUCTURE <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span><span class="Bold">Â  </span>caused by <span class="Italics">Bacteroides </span>species including the <span class="Italics">B. fragilis</span> group, <span class="Italics">Clostridium </span>species, <span class="Italics">Peptococcus niger, Peptostreptococcus </span>species, and <span class="Italics">Fusobacterium </span>species.</p>
<p>GYNECOLOGIC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span>, including <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>, endomyometritis, tubo-ovarian <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, and postsurgical vaginal cuff <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, caused by <span class="Italics">Bacteroides </span>species including the <span class="Italics">B.</span><span class="Italics">fragilis </span>group, <span class="Italics">Clostridium </span>species, <span class="Italics">Peptococcus niger, </span>and <span class="Italics">Peptostreptococcus </span>species.</p>
<p>BACTERIAL <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">SEPTICEMIA</span><span class="Bold">Â  </span>caused by <span class="Italics">Bacteroides </span>species including the <span class="Italics">B. fragilis </span>group, and <span class="Italics">Clostridium </span>species.</p>
<p>BONE AND <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">JOINT INFECTIONS</span>,<span class="Bold">Â  </span>as adjunctive therapy, caused by <span class="Italics">Bacteroides </span>species including the <span class="Italics">B. fragilis </span>group.</p>
<p>CENTRAL NERVOUS SYSTEM (CNS) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span>, including <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and <span class="product-label-link" type="condition" conceptid="435509" conceptname="Intracranial abscess">brain abscess</span>, caused by <span class="Italics">Bacteroides </span>species including the <span class="Italics">B. fragilis </span>group.</p>
<p><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">LOWER RESPIRATORY TRACT INFECTIONS</span>, including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">empyema</span>, and <span class="product-label-link" type="condition" conceptid="257010" conceptname="Abscess of lung">lung abscess</span>, caused by <span class="Italics">Bacteroides </span>species including the <span class="Italics">B. fragilis </span>group.</p>
<p><span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">ENDOCARDITIS</span><span class="Bold">Â  </span>caused by <span class="Italics">Bacteroides </span>species including the <span class="Italics">B. fragilis </span>group.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole, USP and other antibacterial drugs, metronidazole, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. </p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_3dfc9c59-b846-4f4f-9abf-e319207d339a"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Metronidazole is contraindicated in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole or other nitroimidazole derivatives.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span>, metronidazole is contraindicated during the first trimester of pregnancy (see <span class="Bold"><a href="#LINK_1225f5df-ff87-447b-a1dc-dd5958cad3b9">WARNINGS</a></span>). </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_1225f5df-ff87-447b-a1dc-dd5958cad3b9"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Central and Peripheral Nervous System Effects</span></p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, optic and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity, have been reported in patients treated with metronidazole. The appearance of abnormal neurologic signs demands the prompt discontinuation of metronidazole therapy. Metronidazole should be administered with caution to patients with central nervous system diseases.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_197af00a-6e39-4443-aa3b-5b836d585c7f"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_feeeb269-4993-4cfe-a6be-95f679928517"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> metabolize metronidazole slowly, with resultant accumulation of metronidazole and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously.</p>
<p>Known or previously unrecognized <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> may present more prominent symptoms during therapy with metronidazole and requires treatment with a candidacidal agent.</p>
<p>Prescribing metronidazole in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_23e973bc-0391-4d34-8231-166a660c700c"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Alcoholic beverages should be avoided while taking metronidazole and for at least one day afterward (see <span class="Bold"><a href="#LINK_b720eee7-8d2a-4060-bb77-945997fe3d43">Drug Interactions</a></span>).</p>
<p>Patients should be counseled that antibacterial drugs including metronidazole should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When metronidazole is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by metronidazole or other antibacterial drugs in the future. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a0c6eeb7-38a5-4a33-bb8f-54e041b27d53"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Metronidazole is a nitroimidazole and should be used with caution in patients with evidence of or history of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>. A mild <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> has been observed during its administration; however, no persistent hematologic abnormalities attributable to metronidazole have been observed in clinical studies. Total and differential leukocyte counts are recommended before and after therapy for <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> and <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>, especially if a second course of therapy is necessary, and before and after therapy for anaerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b720eee7-8d2a-4060-bb77-945997fe3d43"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. This possible drug interaction should be considered when metronidazole is prescribed for patients on this type of anticoagulant therapy.</p>
<p>The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.</p>
<p>The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of metronidazole. In patients stabilized on relatively high doses of lithium, short-term metronidazole therapy has been associated with elevation of serum lithium, and in a few cases, signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Serum lithium and serum creatinine levels should be obtained several days after beginning metronidazole to detect any increase that may precede clinical symptoms of lithium <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
<p>Alcoholic beverages should not be consumed during metronidazole therapy and for at least one day afterward because <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> may occur.</p>
<p><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Metronidazole should not be given to patients who have taken disulfiram within the last two weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6e73251f-7eb2-4cfa-9e49-69cb26b7a953"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Metronidazole may interfere with certain types of determinations of serum chemistry values, such as <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and hexokinase glucose. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD<span class="Sup">+</span><img alt="Chemical Equation Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5911e8f2-1b3a-4222-b997-d2a1c9a9f535&amp;name=metronidazole-for-pliva-2.jpg">NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5e2687e4-a572-4401-a57f-8e8dc68621b0"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats.</p>
<p>Prominent among the effects in the mouse was the promotion of pulmonary tumorigenesis. This has been observed in all six reported studies in that species, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). At very high dose levels (approx. 500 mg/kg/day which is approximately 33 times the most frequently recommended human dose for a 50 kg adult based on mg/kg body weight) there was a statistically significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span> in males. Also, the published results of one of the mouse studies indicate an increase in the incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span> as well as pulmonary neoplasms associated with lifetime feeding of the drug. All these effects are statistically significant.</p>
<p>Several long-term, oral-dosing studies in the rat have been completed. There were statistically significant increases in the incidence of various neoplasms, particularly in mammary and hepatic tumors, among female rats administered metronidazole over those noted in the concurrent female control groups.</p>
<p>Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative.</p>
<p>Although metronidazole has shown mutagenic activity in a number of <span class="Italics">in vitro </span>assay systems, studies in mammals (<span class="Italics">in vivo</span>) have failed to demonstrate a potential for genetic damage.</p>
<p>Fertility studies have been performed in mice at doses up to six times the maximum recommended human dose based on mg/m<span class="Sup">2</span> and have revealed no evidence of impaired fertility.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_376117a9-992f-4a76-b1e1-913b868929ba"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d1c4a748-a277-4c41-a20d-cfd0009d32e3"></a><a name="section-7.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c5442915-f4a9-4005-984e-77d580fe04c9"></a><a name="section-7.7.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. Reproduction studies have been performed in rats at doses up to five times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to metronidazole. No fetotoxicity was observed when metronidazole was administered orally to pregnant mice at 20 mg/kg/day, approximately one and a half times the most frequently recommended human dose (750 mg/day) based on mg/kg body weight; however in a single small study where the drug was administered intraperitoneally, some intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were observed. The relationship of these findings to the drug is unknown. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because metronidazole is a carcinogen in rodents, this drug should be used during pregnancy only if clearly needed.</p>
<p>Use of metronidazole for <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> during pregnancy should be restricted to those in whom alternative treatment has been inadequate. Use of metronidazole for <span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">trichomoniasis</span> in pregnancy should be carefully evaluated because metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known (see above).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_92ccae3f-7199-4a3d-ab37-b8f413f8ec83"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because of the potential for tumorigenicity, shown for metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Metronidazole is secreted in human milk in concentrations similar to those found in plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3d7d08c7-78b2-45e5-a914-ff47f84e1d49"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole. However, plasma clearance of metronidazole is decreased in patients with decreased liver function. Therefore, in elderly patients, monitoring of serum levels may be necessary to adjust the metronidazole dosage accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e2573e0b-a9be-4e7f-b6e4-a21ff5662e1f"></a><a name="section-7.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established, except for the treatment of <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_7e11d358-d8e8-4a94-b5cb-aefc97631b37"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most serious adverse reactions reported in patients treated with metronidazole have been <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, optic and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity. Since persistent <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> has been reported in some patients receiving prolonged administration of metronidazole, patients should be specifically warned about these reactions and should be told to stop the drug and report immediately to their physicians if any <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> occur.</p>
<p>The most common adverse reactions reported have been referable to the gastrointestinal tract, particularly <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> reported by about 12% of patients, sometimes accompanied by <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and occasionally <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>; and abdominal cramping. <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> has also been reported.</p>
<p>The following reactions have also been reported during treatment with metronidazole: </p>
<p>Mouth: A sharp, unpleasant metallic taste is not unusual. Furry tongue, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> have occurred; these may be associated with a sudden overgrowth of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> which may occur during therapy.</p>
<p>Hematopoietic: Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>); rarely, reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p>Cardiovascular: Flattening of the T-wave may be seen in electrocardiographic tracings.</p>
<p>Central Nervous System: <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="380410" conceptname="Nutritional optic neuropathy">optic neuropathy</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, dryness of the mouth (or vagina or vulva), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p>Renal: <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, and a sense of pelvic pressure. Instances of darkened urine have been reported by approximately one patient in 100,000. Although the pigment which is probably responsible for this phenomenon has not been positively identified, it is almost certainly a metabolite of metronidazole and seems to have no clinical significance.</p>
<p>Other: Proliferation of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span>in the vagina, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, decrease of libido, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, and fleeting <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span> sometimes resembling â€œserum sickness.â€? If patients receiving metronidazole drink alcoholic beverages, they may experience <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. A modification of the taste of alcoholic beverages has also been reported. Rare cases of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, which generally abated on withdrawal of the drug, have been reported.</p>
<p>Crohnâ€™s disease patients are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohnâ€™s disease patients who have been treated with metronidazole at high doses for extended periods of time. A cause and effect relationship has not been established. Crohnâ€™s disease is not an approved indication for metronidazole.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_5221ff16-413b-44a0-88c6-d7453e99d5fa"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Single oral doses of metronidazole, up to 15 g, have been reported in <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> and accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>. Symptoms reported include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>.</p>
<p>Oral metronidazole has been studied as a radiation sensitizer in the treatment of <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span>. Neurotoxic effects, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, have been reported after 5 to 7 days of doses of 6 to 10.4 g every other day.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0a5677f8-4d7a-4a00-b9a6-ca3c504d3ea7"></a><a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">There is no specific antidote for metronidazole <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>; therefore, management</p>
<p>of the patient should consist of symptomatic and supportive therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_eefd0269-6c7d-4ded-9e66-ec902d0a79f4"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">In elderly patients, the pharmacokinetics of metronidazole may be altered, and, therefore, monitoring of serum levels may be necessary to adjust the metronidazole dosage accordingly.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_636ad16d-f11e-4a8e-b9c3-fb262d1fd715"></a><a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434872" conceptname="Infection by Trichomonas">Trichomoniasis</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fe852ea6-97a8-4808-b7e6-4f0d00923f86"></a><a name="section-10.1.1"></a><p></p>
<h3>In the Female</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_875087bc-c2fd-4b66-9656-cf29fe4d6d6a"></a><a name="section-10.1.1.1"></a><p></p>
<h4>One-day treatment</h4>
<p class="First">Â Two grams of metronidazole, given either as a single-dose or in two divided doses of one gram each given in the same day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_beed816a-8a5d-4f37-9dab-a09f49993c0d"></a><a name="section-10.1.1.2"></a><p></p>
<h4>Seven-day course of treatment</h4>
<p class="First">Â 250 mg three times daily for seven consecutive days. </p>
<p>There is some indication from controlled comparative studies that cure rates as determined by vaginal smears, signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen. </p>
<p>The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other.</p>
<p>Pregnant patients should not be treated during the first trimester (see <span class="Bold"><a href="#LINK_3dfc9c59-b846-4f4f-9abf-e319207d339a">CONTRAINDICATIONS</a></span>). In pregnant patients in whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation (see <span class="Bold"><a href="#LINK_376117a9-992f-4a76-b1e1-913b868929ba">PRECAUTIONS, Pregnancy</a></span>).</p>
<p>When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e89486cc-fdb2-41ed-afb1-572f2237a884"></a><a name="section-10.1.2"></a><p></p>
<h3>In the Male</h3>
<p class="First">Treatment should be individualized as for the female.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fa68709c-1efc-46d5-a885-639bb4a8e8c5"></a><a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e907d809-6fe3-4853-bd11-d145a9abffef"></a><a name="section-10.2.1"></a><p></p>
<h3>Adults</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_efcd32fd-5982-46e6-977b-bd64dec2386a"></a><a name="section-10.2.1.1"></a><p></p>
<h4>For acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> (acute amebic <span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">dysentery</span>)</h4>
<p class="First">750 mg orally three times daily for 5 to 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6e8ed50b-e283-4de4-b19b-9814d1601d21"></a><a name="section-10.2.1.2"></a><p></p>
<h4>For amebic <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span></h4>
<p class="First">Â 500 mg or 750 mg orally three times daily for 5 to 10 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ca083518-e867-42e7-a666-4fb3053774fe"></a><a name="section-10.2.2"></a><p></p>
<h3>Pediatric Patients</h3>
<p class="First">35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9ddff123-d311-4cab-89ad-12210be65a3c"></a><a name="section-10.3"></a><p></p>
<h2>Anaerobic <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span></h2>
<p class="First">In the treatment of most serious anaerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the intravenous form of metronidazole is usually administered initially. </p>
<p>The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period. </p>
<p>The usual duration of therapy is 7 to 10 days; however, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.</p>
<p>Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> metabolize metronidazole slowly, with resultant accumulation of metronidazole and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously. Close monitoring of plasma metronidazole levels<span class="Sup">2</span> and toxicity is recommended.</p>
<p>The dose of metronidazole should not be specifically reduced in anuric patients since accumulated metabolites may be rapidly removed by dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_7dd9ab7b-8fe9-4555-bf08-dd0bb2e0e13e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Metronidazole tablets USP are available as follows:</p>
<p>250 mg - White, round, convex tablets debossed â€œ<span class="Bold">PLIVA 333</span>â€? on one side and unscored on the other side. Available in bottles of 28.</p>
<p>500 mg - White, oblong, convex tablets debossed â€œ<span class="Bold">PLIVA 334</span>â€?Â  on one side and unscored on the other side. Available in bottles ofÂ 14.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9fd28ae9-8e84-4262-a6ed-f40dab898714"></a><a name="section-11.1"></a><p></p>
<h2>Storage and Stability</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p><span class="Bold">PROTECT FROM LIGHT</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p>______________________________________________________________________________</p>
<p>1. Proposed standard: PSM-11-Proposed Reference Dilution Procedure for Antimicrobic Susceptibility Testing of Anaerobic Bacteria, National Committee for Clinical Laboratory Standards; and Sutter, et al.: Collaborative Evaluation of a Proposed Reference Dilution Method of Susceptibility Testing of Anaerobic Bacteria, Antimicrob. Agents Chemother. <span class="Italics">16</span>:495-502 (Oct.) 1979; and Tally, et al.: <span class="Italics">In Vitro </span>Activity of Thienamycin, Antimicrob. Agents Chemother. <span class="Italics">14</span>:436-438 (Sept.) 1978.</p>
<p>2. Ralph, E.D., and Kirby, W.M.M.: Bioassay of Metronidazole With Either Anaerobic or Aerobic Incubation, J. Infect. Dis. <span class="Italics">132</span>:587-591 (Nov.) 1975; or Gulaid, et al.: Determination of Metronidazole and Its Major Metabolites in Biological Fluids by High Pressure Liquid Chromatography, Br. J. Clin. Pharmacol. <span class="Italics">6</span>:430-432, 1978.</p>
<p>Manufactured In Czech Republic By:</p>
<p><span class="Bold">TEVA CZECH INDUSTRIES s.r.o.</span></p>
<p>Opava-Komarov, Czech Republic</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Repackaged By :<br>Aidarex Pharmaceuticals LLC,<br>Corona, CA 92880</p>
<p>Rev. A 6/2011</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_9cea72af-fbc9-44cc-a26a-00d43dc81e59"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="IMAGE LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5911e8f2-1b3a-4222-b997-d2a1c9a9f535&amp;name=metronidazole-for-pliva-3.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3aff61d5-28a6-4c6c-b728-128165f10913"></a><a name="section-12.1"></a><p></p>
<h2>Metronidazole Tablets USP, 250 mgÂ 28 Tablets Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 00440<span class="Bold">-1795-28</span><br><span class="Bold">METRONIDAZOLE<br>Tablets USP<br>250 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">28Â TABLETS</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_13c31a7b-dffd-4b3c-b25d-bbc2331f2e64"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="IMAGE LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5911e8f2-1b3a-4222-b997-d2a1c9a9f535&amp;name=metronidazole-for-pliva-4.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_10bfe7e2-c402-4e53-87df-9fe9890b4012"></a><a name="section-13.1"></a><p></p>
<h2>Metronidazole Tablets USP, 500 mg 14 Tablets Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 00440<span class="Bold">-1796-14</span><br><span class="Bold">METRONIDAZOLE<br>Tablets USP<br>500 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">14Â TABLETS</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METRONIDAZOLEÂ 		
					</strong><br><span class="contentTableReg">metronidazole tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0440-1795(NDC:50111-333)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (METRONIDAZOLE) </td>
<td class="formItem">METRONIDAZOLE</td>
<td class="formItem">250Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROGENATED COTTONSEED OIL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PLIVA;333</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0440-1795-28</td>
<td class="formItem">28  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070027</td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METRONIDAZOLEÂ 		
					</strong><br><span class="contentTableReg">metronidazole tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0440-1796(NDC:50111-334)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (METRONIDAZOLE) </td>
<td class="formItem">METRONIDAZOLE</td>
<td class="formItem">500Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROGENATED COTTONSEED OIL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PLIVA;334</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0440-1796-14</td>
<td class="formItem">14  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070033</td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Liberty Pharmaceuticals, Inc.
							(012568840)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fd60fa16-9bd2-4337-b52f-bf71d6e14714</div>
<div>Set id: 5911e8f2-1b3a-4222-b997-d2a1c9a9f535</div>
<div>Version: 1</div>
<div>Effective Time: 20130911</div>
</div>
</div>Â <div class="DistributorName">Liberty Pharmaceuticals, Inc.</div></p>
</body></html>
